Neurofilaments as biomarkers in neurological disorders
By M. Khalil, C. Teunissen, M. Otto, F. Piehl, M. Sormani, T. Gattringer, Christian Barro, L. Kappos, M. Comabella, F. Fazekas and 4 more. Nature Reviews Neurology, 2018
1,788 citations recorded by the source corpus.
Subfields: Cell Biology, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/8ed8e3a5d053ade67dd53c29589d55e8a34eafff
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody (2020, background): “AD diagnosis is associated with increased plaque burden in the brain and a decrease in Aβ1–42 monomers in CSF due to sequestration of monomeric Aβ1–42 into amyloid plaques [26].”
- Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. (2021, neutral): “62,63 This biomarker can be measured in CSF and blood and was the first neuro specific biomarker for which clinical value was proven in a multitude of publications after development of an ultrasensitive assay.”